We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome.
PURPOSE: To report the authors' experience using infliximab to treat 2 patients with Vogt-Koyanagi-Harada disease (VKH).
DESIGN: Interventional case series.
METHODS: Medical records of the 2 patients were reviewed.
RESULTS: After starting infliximab intravenous infusions, 5 mg/kg, both patients experienced rapid improvement in their VKH disease, and were able to taper and discontinue prednisone without disease recurrence for the several-month follow-up period.
CONCLUSIONS: Infliximab may be effective treatment for VKH, and spares patients the side effects of corticosteroids and conventional immunosuppressive drugs.
DESIGN: Interventional case series.
METHODS: Medical records of the 2 patients were reviewed.
RESULTS: After starting infliximab intravenous infusions, 5 mg/kg, both patients experienced rapid improvement in their VKH disease, and were able to taper and discontinue prednisone without disease recurrence for the several-month follow-up period.
CONCLUSIONS: Infliximab may be effective treatment for VKH, and spares patients the side effects of corticosteroids and conventional immunosuppressive drugs.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app